Research Antibodies Is Estimated To Witness High Growth Owing To...

Research Antibodies Is Estimated To Witness High Growth Owing To Rising Demand In Healthcare Industry

Posted 2023-12-15 13:40:26

Research antibodies are monoclonal or polyclonal antibodies used in scientific research that serve as detection reagents or probes for research applications such as ELISA (enzyme-linked immunosorbent assay), Western blot, immunohistochemistry or immunofluorescence. They are used extensively by pharmaceutical and biotech companies, hospitals and pathology labs and contract research organizations for wide range of applications including protein detection, quantification and purification. The global research antibodies market is estimated to be valued at US$ 3785.5 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Rising Demand in Healthcare Industry
Research antibodies are indispensable tools for basic research, drug development and disease diagnostics in healthcare. The ever-growing global healthcare expenditure along with increasing R&D investments of pharmaceutical and biotech companies has augmented the demand for research antibodies to expedite drug discovery and clinical trials. According to World Health Organization, global healthcare spending is expected to increase to $8.7 trillion by 2020 from $7.7 trillion in 2017. This significant rise in healthcare spending stimulates the generation of novel drug targets and biomarkers, thus propelling the market growth of research antibodies.

One Driver from Heading - High Growth Owing to Rising Demand in Healthcare Industry
As mentioned earlier, the growing global healthcare expenditure is fueling the demand for research antibodies from pharmaceutical and biomedical companies for target identification, screening and validation required during drug discovery and development process. Research antibodies help accelerate drug discovery by aiding target identification and validation at molecular level. Thus, surging R&D investments coupled with increasing focus on precision medicine is estimated to boost the adoption of research antibodies significantly over the forecast period.

SWOT Analysis
Strength: Research Antibodies Market provides high specificity and selectivity. Antibodies help researchers understand disease pathology at the molecular level and aid in drug discovery. Availability of custom monoclonal and polyclonal antibodies give researchers options to suit their unique requirements.

Weakness: Producing research-grade antibodies is a complex process involving live animals. This raises ethical concerns around animal welfare. Ensuring batch-to-batch reproducibility can also be challenging.

Opportunity: Growing fields of proteomics, immunology and cancer research are driving new demand. Developing antibodies against novel disease targets presents major opportunities. Adoption of recombinant antibody technologies can help address challenges in traditional production methods.

Threats: Stringent regulations around antibody production may raise costs. Increased competition from Asia could pressure pricing. Political and economic instability worldwide may disrupt supply chains.

Key Takeaways

The global Research Antibodies Market Share is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to rise from US$ 3785.5 Bn in 2023 to over US$ 6500 Bn by 2030, reflecting a CAGR of around 5.9%.

North America currently dominates the market due to extensive research activities in the region. The United States accounts for the largest share of over 35% of the global market. However, Asia Pacific is poised to emerge as the fastest growing regional market. Countries such as China, India and South Korea are introducing initiatives to boost laboratory infrastructure and biomedical research. This is attracting significant antibody producer investments into Asia.

Key players operating in the Research Antibodies market are Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc. These companies are focusing on developing novel antibody technologies and broadening their product portfolios to tap new applications and markets. Collaboration with research institutions is another key strategy to support discovery.